Elevance Health (ELV) Projected to Post Quarterly Earnings on Tuesday

Elevance Health (NYSE:ELV) is anticipated to issue its Q3 2025 results before the market opens on Tuesday, October 21st. Analysts expect the company to announce earnings of $5.03 per share and revenue of $49.2626 billion for the quarter. Individuals may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Tuesday, October 21, 2025 at 8:30 AM ET.

Elevance Health (NYSE:ELV) last released its earnings results on Thursday, July 17th. The company reported $8.84 EPS for the quarter, missing analysts’ consensus estimates of $9.30 by ($0.46). Elevance Health had a return on equity of 17.59% and a net margin of 2.83%.The company had revenue of $49.42 billion during the quarter, compared to analysts’ expectations of $48.26 billion. During the same period in the prior year, the company posted $10.12 earnings per share. The company’s revenue was up 14.3% on a year-over-year basis. On average, analysts expect Elevance Health to post $34 EPS for the current fiscal year and $39 EPS for the next fiscal year.

Elevance Health Trading Up 0.2%

NYSE ELV opened at $348.93 on Monday. Elevance Health has a 12 month low of $273.71 and a 12 month high of $458.75. The stock has a market cap of $78.57 billion, a P/E ratio of 14.85, a P/E/G ratio of 1.27 and a beta of 0.59. The stock’s fifty day moving average price is $321.94 and its 200-day moving average price is $355.13. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Barclays increased their price objective on Elevance Health from $373.00 to $395.00 and gave the company an “overweight” rating in a research report on Thursday, October 9th. The Goldman Sachs Group assumed coverage on Elevance Health in a report on Tuesday, October 14th. They issued a “neutral” rating and a $343.00 price objective for the company. Morgan Stanley increased their target price on Elevance Health from $316.00 to $359.00 and gave the company an “equal weight” rating in a report on Tuesday, October 14th. Wall Street Zen downgraded Elevance Health from a “buy” rating to a “hold” rating in a report on Friday, July 18th. Finally, Weiss Ratings raised Elevance Health from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, October 8th. Eleven research analysts have rated the stock with a Buy rating and ten have given a Hold rating to the company. According to MarketBeat.com, Elevance Health currently has an average rating of “Moderate Buy” and a consensus price target of $404.72.

Insider Buying and Selling

In related news, Director Susan D. Devore purchased 1,200 shares of Elevance Health stock in a transaction on Tuesday, August 19th. The stock was acquired at an average price of $312.15 per share, for a total transaction of $374,580.00. Following the completion of the transaction, the director directly owned 3,502 shares in the company, valued at $1,093,149.30. This represents a 52.13% increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.29% of the stock is currently owned by insiders.

Institutional Trading of Elevance Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. State of Wyoming purchased a new stake in Elevance Health in the second quarter worth about $127,000. Transamerica Financial Advisors LLC increased its position in Elevance Health by 43.9% in the second quarter. Transamerica Financial Advisors LLC now owns 616 shares of the company’s stock worth $239,000 after buying an additional 188 shares in the last quarter. MUFG Securities EMEA plc purchased a new stake in Elevance Health in the second quarter worth about $260,000. Kestra Investment Management LLC increased its position in Elevance Health by 20.8% in the second quarter. Kestra Investment Management LLC now owns 709 shares of the company’s stock worth $276,000 after buying an additional 122 shares in the last quarter. Finally, Occudo Quantitative Strategies LP purchased a new stake in Elevance Health in the second quarter worth about $363,000. Hedge funds and other institutional investors own 89.24% of the company’s stock.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.